Livoletide
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT02040012)
Timeline
Indications
Mechanism of action
- ChondrocyteAGONIST
Chondrocyte agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC1=O- Mol. weight
- 962.04 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2029605 ↗
Also known as
- azp-531
- azp-531
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03790865 | Phase 2/Phase 3 (Phase 3) | Mar 26, 2019 | Millendo Therapeutics, Inc. |
| NCT02040012 | Phase 1 | Jul 1, 2013 | Alizé Pharma, IQVIA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alizé Pharma | For profit | 1 | 1 | 1 | 2013 |
| IQVIA | For profit | 1 | 0 | 1 | 2013 |
| Millendo Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1